Skip to main
OCS

OCS Stock Forecast & Price Target

OCS Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oculis Holding is set to release results from the phase 3 DIAMOND trials of OCS-01 in June, with the potential to be the first topical drug approved for retinal disorders and address significant unmet needs in the diabetic macular edema (DME) market. Despite facing financing risks, the company has a strong cash position and is also working on developing innovative treatments for dry eye disease (DED) and optic neuritis, which have potential multi-billion dollar markets. With multiple highly-differentiated product candidates and the recent breakthrough therapy designation for their optic neuritis treatment, Oculis Holding appears to have a promising future ahead.

Bears say

Oculis Holding is currently in a high-risk development stage, with its success dependent on securing payor access/reimbursement and the completion of clinical trials and gaining FDA approval for its three assets. Although the company has received positive agreements and designations from the FDA, there is no guarantee that its products will be successful in their various indications. Furthermore, with only one asset currently in Phase 3 trials and the potential for market competition, there are risks associated with the company's future financial stability.

OCS has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oculis Holding AG and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oculis Holding AG (OCS) Forecast

Analysts have given OCS a Strong Buy based on their latest research and market trends.

According to 9 analysts, OCS has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oculis Holding AG (OCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.